Aarhus Universitets segl

English

Du er her: AU » Om AU » Organisation » Oncological and Peri-Operative Outcomes of Percutaneous C...

Om AU

Oncological and Peri-Operative Outcomes of Percutaneous Cryoablation of Renal Cell Carcinoma for Patients with Hereditary RCC Diseases—An Analysis of European Multi-Centre Prospective EuRECA Registry

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

DOI

  • Filzah Hanis Osman, University of Leeds
    • ,
  • Vinson Wai Shun Chan, University of Leeds, University of Nottingham, University College London
    • ,
  • David J. Breen, Southampton University Hospitals NHS Trust
    • ,
  • Alexander King, Southampton University Hospitals NHS Trust
    • ,
  • Tommy Kjærgaard Nielsen
  • Julien Garnon, Hopital Civil
    • ,
  • Des Alcorn, Gartnavel General Hospital
    • ,
  • Brunolf Lagerveld, Onze Lieve Vrouwe Gasthuis
    • ,
  • Ole Graumann
  • Francis Xavier Keeley, North Bristol NHS Trust
    • ,
  • Miles Walkden, University College London
    • ,
  • Éric de Kerviler, Université Paris Cité (Paris V, Paris VII)
    • ,
  • Tze Min Wah, University of Leeds

This study aims to evaluate the safety, efficacy, and renal function preservation of percutaneous cryoablation (PCA) for small renal masses (SRMs) in inherited RCC syndromes. Patients with inherited T1N0M0 RCCs (<7 cm) undergoing PCA from 2015 to 2021 were identified from the European Registry for Renal Cryoablation (EuRECA). The primary outcome was local recurrence-free survival (LRFS). The secondary outcomes included technical success, peri-operative outcomes, and other oncological outcomes estimated using the Kaplan–Meier method. Simple proportions, chi-squared tests, and t-tests were used to analyse the peri-operative outcomes. A total of 68 sessions of PCA were performed in 53 patients with RCC and 85 tumours were followed-up for a mean duration of 30.4 months (SD ± 22.0). The overall technical success rate was 99%. The major post-operative complication rate was 1.7%. In total, 7.4% (2/27) of patients had >25% reduction in renal function. All oncological events were observed in VHL patients. Estimated 5-year LRFS, metastasis-free survival, cancer-specific survival, and overall survival were 96.0% (95% CI 75–99%), 96.4% (95% CI 77–99%), 90.9% (95% CI 51–99%), and 90.9% (95% CI 51–99%), respectively. PCA of RCCs for patients with hereditary RCC SRMs appears to be safe, offers low complication rates, preserves renal function, and achieves good oncological outcomes.

OriginalsprogEngelsk
Artikelnummer3322
TidsskriftCancers
Vol/bind15
Nummer13
ISSN2072-6694
DOI
StatusUdgivet - jul. 2023

Se relationer på Aarhus Universitet Citationsformater

ID: 339838695